
Evotec Announces SBTi Approval for Its Net-Zero Science-Based Targets

- *Evotec's net-zero target ambitions have been validated by the Science-Based Targets initiative ("SBTi") as being in line with a 1.5°C trajectory*
-

Hamburg, 07 November 2024:

Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company's greenhouse gas ("GHG") near-term and long-term emissions reduction targets have been validated and approved by the Science Based Targets initiative ("SBTi"). Further, the SBTi has verified Evotec's net-zero science-based target by 2045 and has classified Evotec's Scope 1 and 2 target ambitions as being in line with a 1.5°C trajectory.

Evotec is committed to:

1. **Overall Net-Zero Target:** Evotec SE commits to reach net-zero greenhouse gas emissions across the value chain by 2045.
2. **Near-Term Targets:** Evotec SE commits to reduce absolute scope 1 and 2 GHG emissions 50.4% by 2032 from a 2021 base year. Evotec SE also commits to increase active annual sourcing of renewable electricity from 25% in 2021 to 100% by 2026, and to continue active annual sourcing of 100% renewable electricity through 2030. Evotec SE commits to reduce scope 3 GHG from purchased goods and services and capital goods 72% per million EUR value added by 2032 from a 2021 base year. Evotec also commits that 80% of its suppliers by emissions covering purchased goods and services and capital goods will have science-based targets by 2027.
3. **Long-Term Targets:** Evotec SE commits to reduce absolute scope 1 and 2 GHG emissions 95% by 2045 from a 2021 base year. Evotec SE also commits to reduce scope 3 GHG emissions by 97% per million EUR value added within the same timeframe.

The SBTi defines and promotes best practice in science-based target setting and independently assesses and validates companies' targets to increase accountability and credibility of corporate climate action. Evotec's Management signed the pledge to the Science Based Targets initiative (SBTi) in December 2020, committing to set targets aligned with the goals of the Paris Agreement, and Evotec submitted the net-zero targets to the SBTi in January 2024:

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, commented:

"We are proudly taking proactive steps to reduce our greenhouse gas emissions, and feel encouraged that the Science Based Targets initiative has classified our net-zero target as aligned with the SBTi Corporate



Net-Zero Standard. We strongly believe that we can create a healthier and more sustainable future together with our partners. SBTi's validation and approval of our net-zero targets reflects our commitment to transparency, accountability, and meaningful climate action aligned with science."

More information about Evotec's efforts to reduce greenhouse gas emissions can be found in the Company's [Sustainability Report](#), and the [SBTi dashboard](#).

About Evotec SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter [@Evotec](#) and [LinkedIn](#).

About Science Based Targets initiative

The Science Based Targets initiative ("SBTi") drives ambitious climate action in the private sector by enabling organisations to set science-based emissions reduction targets. The SBTi is a partnership between CDP, the United Nations Global Compact, World Resources Institute ("WRI") and the World Wide Fund for Nature ("WWF"). Science-based targets provide companies with a clearly defined path for companies to reduce greenhouse gas (GHG) emissions in line with the Paris Agreement goals. For additional information please visit <https://sciencebasedtargets.org>.

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Investor Relations

Volker Braun

EVP Head of Global Investor Relations & ESG

Volker.Braun@evotec.com

Media

Susanne Kreuter

VP Head of Strategic Marketing

Susanne.Kreuter@evotec.com